PMID- 21348302
OWN - NLM
STAT- MEDLINE
DCOM- 20120919
LR  - 20110224
IS  - 0513-4870 (Print)
IS  - 0513-4870 (Linking)
VI  - 45
IP  - 10
DP  - 2010 Oct
TI  - [Synergistic effect and its possible mechanisms of lidamycin in combination with 
      TRAIL in NSCLC].
PG  - 1247-53
AB  - This study is to investigate the effect and its possible mechanisms of lidamycin 
      (LDM) combined with tumor necrosis factor-related apoptosis-inducing ligand 
      (TRAIL) in human non-small cell lung cancer (NSCLC) cells. MTT assay was used to 
      determine the growth inhibition of the two ingredients on H460 cells. Apoptosis 
      was examined by Annexin V-FITC/PI staining, flow cytometry assay and DNA-specific 
      dye Hoechst 33342 staining. The level of TRAIL receptor and apoptosis-associated 
      protein expression was detected by Western blotting analysis. The results showed 
      that the IC50 value of LDM and TRAIL for H460 cells was 4.603 x 10(-10) mol x 
      L(-1) and 915.3 ng x mL(-1) respectively, but the IC50 value of LDM was 3.064 x 
      10(-11) mol x L(-1) and 1.611 x 10(-11) mol x L(-1) when different concentrations 
      of LDM was combined with 50 and 100 ng x mL(-1) TRAIL respectively. And the CDI 
      value was less than 1. The apoptosis ratios also increased in the combination 
      group relative to the single-agent treatment and the untreated control. 
      Furthermore, the induction of the cleavage of PARP and the activation of 
      Caspase-3 and Caspase-8 by the combination were more effective than LDM or TRAIL 
      alone. At last, the level of death receptor 5 (DR5) expressions increased in a 
      dose-dependent manner and time-related pattern. The data indicate that LDM 
      inhibits the growth of H460 cells in vitro. DR5 induction contributes to 
      enhancement of TRAIL-induced apoptosis by LDM in human non-small lung cancer 
      cells.
FAU - Yang, Jie
AU  - Yang J
AD  - Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & 
      Peking Union Medical College, Beijing 100050, China.
FAU - Chen, Shu-zhen
AU  - Chen SZ
LA  - chi
PT  - English Abstract
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Yao Xue Xue Bao
JT  - Yao xue xue bao = Acta pharmaceutica Sinica
JID - 21710340R
RN  - 0 (Aminoglycosides)
RN  - 0 (Antibiotics, Antineoplastic)
RN  - 0 (Enediynes)
RN  - 0 (Receptors, TNF-Related Apoptosis-Inducing Ligand)
RN  - 0 (TNF-Related Apoptosis-Inducing Ligand)
RN  - 120177-69-7 (C 1027)
RN  - EC 2.4.2.30 (Poly(ADP-ribose) Polymerases)
RN  - EC 3.4.22.- (CASP3 protein, human)
RN  - EC 3.4.22.- (CASP8 protein, human)
RN  - EC 3.4.22.- (Caspase 3)
RN  - EC 3.4.22.- (Caspase 8)
SB  - IM
MH  - Aminoglycosides/administration & dosage/*pharmacology
MH  - Antibiotics, Antineoplastic/administration & dosage/pharmacology
MH  - Apoptosis/*drug effects
MH  - Carcinoma, Non-Small-Cell Lung/metabolism/*pathology
MH  - Caspase 3/metabolism
MH  - Caspase 8/metabolism
MH  - Cell Line, Tumor
MH  - Cell Survival/drug effects
MH  - Dose-Response Relationship, Drug
MH  - Drug Synergism
MH  - Enediynes/administration & dosage/*pharmacology
MH  - Humans
MH  - Lung Neoplasms/metabolism/*pathology
MH  - Poly(ADP-ribose) Polymerases/metabolism
MH  - Receptors, TNF-Related Apoptosis-Inducing Ligand/*metabolism
MH  - TNF-Related Apoptosis-Inducing Ligand/administration & dosage/*pharmacology
EDAT- 2011/02/26 06:00
MHDA- 2012/09/20 06:00
CRDT- 2011/02/26 06:00
PHST- 2011/02/26 06:00 [entrez]
PHST- 2011/02/26 06:00 [pubmed]
PHST- 2012/09/20 06:00 [medline]
PST - ppublish
SO  - Yao Xue Xue Bao. 2010 Oct;45(10):1247-53.